STAT3 and colonic neoplasm: Further studies reported that apatinib inhibited PD-L1 expression by targeting signal transducer and activator of transcription 3 (STAT3) in osteosarcoma [17], while promoted its expression to enhance anti-PD-1 therapy in colon cancer [18].